Determining fitness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments

ESMO Open. 2024 Nov;9(11):103985. doi: 10.1016/j.esmoop.2024.103985. Epub 2024 Nov 13.

Authors

B M Russell¹, D E C Fein², J Bellmunt³

Affiliations

¹ Beth Israel Deaconess Medical Center, Boston, USA. Electronic address: bmrussel@bidmc.harvard.edu.
² Beth Israel Deaconess Medical Center, Boston, USA.
³ Dana Farber Cancer Institute, Boston, USA.

No abstract available

Publication types

Letter